Lifecome Biochemistry Co.,Ltd.
SZSE:002868.SZ
24.39 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 649.373 | 507.005 | 329.85 | 363.386 | 308.145 | 303.76 | 344.292 | 375.411 | 401.49 | 385.613 | 295.776 | 297.151 | 306.556 |
| Cost of Revenue
| 703.705 | 611.749 | 339.104 | 303.799 | 214.62 | 202.733 | 225.382 | 223.579 | 243.989 | 243.02 | 210.348 | 211.256 | 204.065 |
| Gross Profit
| -54.332 | -104.745 | -9.254 | 59.588 | 93.526 | 101.027 | 118.91 | 151.832 | 157.502 | 142.593 | 85.428 | 85.894 | 102.491 |
| Gross Profit Ratio
| -0.084 | -0.207 | -0.028 | 0.164 | 0.304 | 0.333 | 0.345 | 0.404 | 0.392 | 0.37 | 0.289 | 0.289 | 0.334 |
| Reseach & Development Expenses
| 35.557 | 31.958 | 21.825 | 24.821 | 19.913 | 18.55 | 14.567 | 14.107 | 13.171 | 13.016 | 11.771 | 14.544 | 11.719 |
| General & Administrative Expenses
| 15.219 | 12.343 | 5.946 | 4.985 | 5.334 | 2.999 | 3.064 | 4.434 | 3.433 | 3.505 | 2.365 | 26.731 | 21.188 |
| Selling & Marketing Expenses
| 7.434 | 15.926 | 10.815 | 14.969 | 11.885 | 21.186 | 20.829 | 20.528 | 22.238 | 20.969 | 16.445 | 15.464 | 16.408 |
| SG&A
| 22.653 | 27.171 | 16.761 | 19.954 | 17.219 | 24.184 | 23.893 | 24.962 | 25.67 | 24.474 | 18.81 | 42.194 | 37.595 |
| Other Expenses
| 315.482 | 72.259 | 12.109 | 15.527 | 12.625 | 8.657 | -0.074 | -0.311 | 7.824 | 6.42 | 3.8 | 10.458 | 1.67 |
| Operating Expenses
| 373.692 | 131.387 | 50.695 | 60.302 | 49.757 | 51.391 | 47.035 | 46.625 | 53.607 | 51.247 | 41.623 | 44.094 | 39.42 |
| Operating Income
| -428.024 | -236.132 | -133.76 | -21.291 | 48.023 | 66.985 | 87.197 | 100.573 | 104.31 | 87.849 | 32.866 | 28.202 | 48.617 |
| Operating Income Ratio
| -0.659 | -0.466 | -0.406 | -0.059 | 0.156 | 0.221 | 0.253 | 0.268 | 0.26 | 0.228 | 0.111 | 0.095 | 0.159 |
| Total Other Income Expenses Net
| -0.126 | -4.762 | -0.351 | 0.729 | 1.202 | -0.979 | -0.074 | -0.311 | 3.931 | 3.959 | 3.749 | 10.458 | 1.67 |
| Income Before Tax
| -428.15 | -240.893 | -134.11 | -32.35 | 48.442 | 66.007 | 87.123 | 100.263 | 108.241 | 91.808 | 36.615 | 38.659 | 50.287 |
| Income Before Tax Ratio
| -0.659 | -0.475 | -0.407 | -0.089 | 0.157 | 0.217 | 0.253 | 0.267 | 0.27 | 0.238 | 0.124 | 0.13 | 0.164 |
| Income Tax Expense
| 17.827 | -18.276 | -11.389 | -5.906 | 5.506 | 9.175 | 12.434 | 14.338 | 15.88 | 13.704 | 5.165 | 5.689 | 7.047 |
| Net Income
| -444.864 | -221.818 | -122.722 | -26.444 | 43.208 | 56.966 | 74.689 | 85.925 | 92.361 | 78.105 | 31.449 | 32.97 | 43.241 |
| Net Income Ratio
| -0.685 | -0.438 | -0.372 | -0.073 | 0.14 | 0.188 | 0.217 | 0.229 | 0.23 | 0.203 | 0.106 | 0.111 | 0.141 |
| EPS
| -2.86 | -1.44 | -0.8 | -0.17 | 0.28 | 0.37 | 0.48 | 0.6 | 0.79 | 0.67 | 0.27 | 0.28 | 0.37 |
| EPS Diluted
| -2.86 | -1.44 | -0.8 | -0.17 | 0.28 | 0.37 | 0.48 | 0.6 | 0.79 | 0.67 | 0.27 | 0.28 | 0.37 |
| EBITDA
| -265.996 | -127.925 | -53.719 | 12.65 | 79.877 | 95.76 | 91.749 | 128.839 | 113.437 | 118.543 | 74.038 | 41.8 | 63.071 |
| EBITDA Ratio
| -0.41 | -0.252 | -0.163 | 0.035 | 0.259 | 0.315 | 0.266 | 0.343 | 0.283 | 0.307 | 0.25 | 0.141 | 0.206 |